PDCD1 and classic Hodgkin lymphoma: We previously reported that among relapsed/refractory patients with classical Hodgkin lymphoma (cHL), 71% of anti–PD-1–naive patients were evaluated as having achieved complete remission (CR) after decitabine-plus-anti–PD-1 combination, versus 32% of patients having achieved CR with anti–PD-1 single-agent camrelizumab (18).